Galmed Pharma (GLMD) Tops Q3 EPS by 19c
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASML Holdings (ASML) Tops Q2 EPS by 59c; offers guidance
- Morgan Stanley Assumes Edenred (EDEN:FP) (EDNMY) at Overweight
- Morgan Stanley Assumes Pluxee France SA (PLX:FP) at Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
